120 related articles for article (PubMed ID: 22173662)
1. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
William WN; Kies MS; Fossella FV; Liu DD; Gladish G; Tse WH; Lee JJ; Hong WK; Lippman SM; Kim ES
Cancer; 2010 May; 116(10):2401-8. PubMed ID: 20225327
[TBL] [Abstract][Full Text] [Related]
3. Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis.
Chen Z; Zhong B; Lun X; Lai Y; Bella AE; Yang W; Wu J
Medicine (Baltimore); 2015 Jun; 94(24):e975. PubMed ID: 26091469
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
Kasliwal S; K R; Reddy P; Maharaj N; M G; Adhav A; Harsh K; Madnoorkar N; Diwan A; Gupta M; Patel G; J SB; Dvorkin MV
South Asian J Cancer; 2024 Jan; 13(1):66-76. PubMed ID: 38721097
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer.
Qi H; Zhang W; Chen B; Zhan Q; Wang T; Shi H; Liu Y; Wang Y; Zhong M; Shi X; Shen F; Li Q
Curr Med Res Opin; 2024 Mar; 40(3):441-453. PubMed ID: 38193524
[TBL] [Abstract][Full Text] [Related]
6. Favorable treatment response of bevacizumab-combined chemotherapy for advanced or recurrent invasive mucinous adenocarcinoma of the lung: A retrospective observational study.
Fujimoto K; Sekine A; Hagiwara E; Asaoka M; Ikeda S; Baba T; Komatsu S; Ogura T
Respir Investig; 2024 May; 62(3):360-364. PubMed ID: 38428089
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.
Hornstein NJ; Zeineddine MA; Gunes BB; Pellatt AJ; Knafl M; Zhu H; Willett AF; Yousef A; Liu S; Sun R; Futreal A; Woodman SE; Taggart MW; Overman MJ; Halperin DM; Raghav KP; Shen JP
Cancer Res Commun; 2024 May; 4(5):1363-1368. PubMed ID: 38709066
[TBL] [Abstract][Full Text] [Related]
8. Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis.
Hu B; Zhou X; Liu Y; Li Q; Xiang M; Zou B; Peng F; Huang M; Gong Y; Zhu J; Wang Y; Ren L; Xu Y; Zhang Y; Li Y; Yu M; Xue J; Deng L; Wang J; Ding Z; Lu Y
Oncol Lett; 2018 Apr; 15(4):5671-5679. PubMed ID: 29556304
[TBL] [Abstract][Full Text] [Related]
9. Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.
Herder G; Codrington H; Colder CD; Aerts JG
Lung Cancer (Auckl); 2013; 4():55-59. PubMed ID: 28210135
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Pérez-Wert P; Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Lecumberri A; Cacho Lavin D; Losantos García I; Fernández Montes A; Cano JM; Limón ML; Hernández San Gil R; Diez M; Vidal Tocino R; Macías Declara I; Visa L; Pimentel Cáceres P; Gil Raga M; Martínez Moreno E; Sauri T; Martín Richard M; Granja M; Cerdà P; Gómez González L; Mérida-García A; Ruiz Martín M; Gallego J;
Gastric Cancer; 2024 Jan; 27(1):131-145. PubMed ID: 37964032
[TBL] [Abstract][Full Text] [Related]
11. A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.
Defferrari C; Campora S; D'Amico M; Piccardo A; Biscaldi E; Rosselli D; Pasa A; Puntoni M; Gozza A; Gennari A; Zanardi S; Lionetto R; Bandelloni M; Decensi A
J Ovarian Res; 2012 Jun; 5(1):17. PubMed ID: 22732001
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.
Haslam S; Chrisp P
Core Evid; 2007 Mar; 2(1):31-49. PubMed ID: 21221196
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Recurrent Breast Cancer with Delayed Wound Healing Induced by Bevacizumab].
Terasawa R; Hirata A; Aoki C; Kimura K; Morita S; Hayashi M
Gan To Kagaku Ryoho; 2024 Mar; 51(3):287-289. PubMed ID: 38494810
[TBL] [Abstract][Full Text] [Related]
14. Treating advanced non-small cell lung cancer in the elderly.
Maione P; Rossi A; Sacco PC; Bareschino MA; Schettino C; Ferrara ML; Falanga M; Ambrosio R; Gridelli C
Ther Adv Med Oncol; 2010 Jul; 2(4):251-60. PubMed ID: 21789138
[TBL] [Abstract][Full Text] [Related]
15. A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.
Mayer T; Lacy J; Baehring J
Clin Med Oncol; 2008; 2():455-9. PubMed ID: 21892317
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer therapy: safety and efficacy in the elderly.
Glotzer OS; Fabian T; Chandra A; Bakhos CT
Drug Healthc Patient Saf; 2013; 5():113-21. PubMed ID: 23637560
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
[TBL] [Abstract][Full Text] [Related]
18. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
19. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R
J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346
[TBL] [Abstract][Full Text] [Related]
20. Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
Langer CJ; Socinski MA; Patel JD; Sandler AB; Schiller JH; Leon L; Hazard SJ; Ramalingam SS
Am J Clin Oncol; 2016 Oct; 39(5):441-7. PubMed ID: 25628268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
